Nexstim Plc (HEL:NXTMH)
Finland · Delayed Price · Currency is EUR | Market Cap | 65.77M +15.9% |
| Revenue (ttm) | 12.41M +21.5% |
| Net Income | 573.20K |
| EPS | 0.06 |
| Shares Out | 7.23M |
| PE Ratio | 151.50 |
| Forward PE | 75.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,534 |
| Average Volume | 4,395 |
| Open | 9.15 |
| Previous Close | 9.16 |
| Day's Range | 8.90 - 9.15 |
| 52-Week Range | 7.42 - 16.45 |
| Beta | 0.45 |
| RSI | 45.57 |
| Earnings Date | Aug 14, 2026 |
About Nexstim
Nexstim Plc, a medical technology company, engages in the development and marketing of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally. The company's proprietary SmartFocus technology with 3D navigation is the navigated transcranial magnetic stimulation (TMS) approach that is used for therapeutic and diagnostic applications. It offers NBT system, a navigated brain therapy system for the treatment of major depression and chronic neuropathic pain; and NBS system, a navigated brain stimula... [Read more]
Financial Performance
Financial StatementsNews
Nexstim Earnings Call Transcript: H2 2025
Revenue grew 26% to EUR 11m in 2025, with record system sales and high gross margins. Strategic partnerships and new product launches drove growth, while recurring revenue saw a temporary dip due to customer purchasing shifts.
Nexstim Transcript: Life Science Summit 2025
The company leverages proprietary TMS technology for brain diagnostics and therapy, achieving strong sales growth, high margins, and profitability. Strategic partnerships and international expansion, especially in Asia, are key growth drivers, while long sales cycles and hospital budget constraints remain challenges.
Nexstim Earnings Call Transcript: H1 2025
Revenue grew 42% in H1 2025, led by diagnostics and new partnerships, with positive EBITDA and strong gross margins. Outlook for 2025 remains positive, supported by the launch of the modular NBS 6 system and continued expansion in diagnostics, therapy, and research.
Nexstim Earnings Call Transcript: H2 2024
Net sales grew 21% to EUR 8.7 million in 2024, with therapy business up 42% and EBITDA positive for the first time. Strategic partnerships with Brainlab and Sinaptica, plus the upcoming NBS 6 diagnostic launch, support a positive 2025 outlook.
Nexstim Earnings Call Transcript: H1 2024
H1 2024 delivered 27% net sales growth, improved profitability, and strong recurring revenue, with both diagnostic and therapy segments contributing equally. Strategic partnerships and new product launches support a positive outlook for the full year.